PDUFA pact creates dedicated FDA fund to rebuild review staff
Pharmaceutical trade groups said the new PDUFA agreement gives the FDA a dedicated funding pool to replenish its reviewer workforce after HHS layoffs. The move aims to restore drug review capacity.
The PDUFA agreement establishes a separate funding stream for the FDA, according to pharmaceutical trade groups. Its purpose is to help the agency refill drug review positions that were lost amid HHS layoffs. The groups framed the fund as a way to rebuild the reviewer ranks and recover review capacity.
The arrangement reflects concern that staffing cuts had weakened the FDA's ability to assess new medicines. By tying money specifically to reviewer workforce needs, the pact seeks to make rebuilding that capacity a defined priority rather than a general budget matter.
If the dedicated fund restores FDA review staffing, patients and developers could see more predictable timelines for new drug decisions. Pharmaceutical companies may benefit from clearer review capacity, while the public may gain from a regulator better able to evaluate safety and effectiveness. The effect depends on how quickly positions are filled and whether funding remains stable. People awaiting new therapies may be most directly affected, though broader health outcomes may take time to emerge.